BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma

SIMPLE SUMMARY: Approximately 60% of all melanomas are associated with a constitutive activating BRAF mutation. Inhibition of BRAF downstream signaling by targeted therapies significantly improved patient outcomes. However, most patients eventually develop resistance. Here we identified miR-129-5p a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebhardt, Kathleen, Edemir, Bayram, Groß, Elisabeth, Nemetschke, Linda, Kewitz-Hempel, Stefanie, Moritz, Rose K. C., Sunderkötter, Cord, Gerloff, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155874/
https://www.ncbi.nlm.nih.gov/pubmed/34063443
http://dx.doi.org/10.3390/cancers13102393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155874/
https://www.ncbi.nlm.nih.gov/pubmed/34063443
http://dx.doi.org/10.3390/cancers13102393

Ejemplares similares